Novo Nordisk has lifted the curtain on much-anticipated results data from the first of ten Phase 3 trials into the efficacy of semaglutide when administered as a once-daily oral tablet in the treatment of type 2 diabetes in adults.
The study utilised two distinct criteria for assessing the drug’s efficacy, evaluating endpoints both taking into account and disregarding patient adherence to the medication. 703 participants were randomised to receive one of three doses of the drug: 3mg, 7mg or 14mg, while another group received placebo.
